Inclusion Criteria:

- Patient must sign informed consent to participate in the study.

- Patient must be ≥ 18 years of age.

- Histologic diagnosis of invasive breast cancer(ductal or lobular)

- Stage II or III breast cancer and considered a candidate for curative mastectomy.

- Selected mastectomy for surgical option of treatment.

- Patient must agree to receive standard or dose-dense adriamycin, cyclophosphamide,
and taxane-based chemotherapy given preoperatively.

- Patient must have the following preoperative laboratory values confirmed within 28
days prior to registration: Creatinine ≤ 1.5 times ULN. Platelets ≥ 90,000/mm3. White
blood count ≥ 1,500/mm3. PT/PTT ≤ the institution ULN. Patients of child-bearing
potential must have a negative urine or serum pregnancy test.

- If a patient is a cancer survivor, the patient must have undergone potentially
curative therapy for all prior malignancies, with no evidence of prior malignancy for
at least 5 years (except for effectively treated basal cell or squamous cell
carcinoma of the skin, or carcinoma-in-situ of the cervix treated by surgery alone).

- The primary breast tumor must be detectable by mammogram at the time of diagnosis

- Estimated cardiac ejection fraction ≥ 50% by echocardiogram or MUGA

- ECOG performance status 0-1.

Exclusion Criteria:

- Non-invasive breast cancer, benign breast disease, or tumor histology other than
stage II or stage III invasive ductal carcinoma, invasive lobular carcinoma, or mixed
ductal and lobular carcinoma.

- The patient has known distant metastatic disease.

- The patient wishes to pursue breast conservation.

- The patient is male.

- The patient is receiving preoperative chemotherapy other than adriamycin,
cyclophosphamide, and a taxane (ACT) in standard or dose-dense fashion.

- The patient is pregnant or breast feeding.

- The primary tumor is not visualized by mammogram at the time of diagnosis.

- The patient's estimated cardiac ejection fraction is <50% by echocardiogram or MUGA.

- The patient has a documented intravenous contrast allergy or iodine allergy.

- Her-2/neu positive patients by IHC or FISH who receive trastuzumab neoadjuvantly;
patients who are Her-2/neu positive but elect not to receive trastuzumab
neoadjuvantly are still eligible for participation.